Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2026
Comparative Outcomes of Late Versus Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gheith Osama, Abdul-Moneem Mohamed, Shaker Mohamed, Alserwy Nabil, Adel Mohamed, Denewar Ahmed, Maher Ayman, Dahab Mohamed, Abdultawab Khalid, Alawady Medhat, Al-Otaibi Torki
Аннотация
OBJECTIVES: Late and chronic active antibody -mediated rejection represents distinct phenotypes after kidney transplant, yet their comparative outcomes remain poorly defined. This study compared clinical outcomes, treatment patterns, and long -term graft survival between late and chronic active antibody -mediated rejection.
MATERIALS AND METHODS: This single -center retrospective cohort study included 111 kidney transplant recipients with biopsy-proven antibody -mediated rejection (50 late, 61 chronic active ) between 2009 and 2024. Groups were matched on baseline demographics, donor type, comorbidities, and maintenance immunosuppression. Outcomes included treatment intensity, complications, renal function, and 5 -year graft survival.
RESULTS: Both groups had comparable baseline characteristics. Patients with late antibody-mediated rejection received significantly more intensive therapy: higher rituximab use (52.0 % vs 34.4 %; P = . ⁰⁰¹ ), more plasma exchange sessions (5.04 vs 2.11; P < . ⁰⁰¹ );, and higher rituximab doses (513.4 vs 252.6 mg; P = . ⁰⁰⁴ ). Patients with late antibody -mediated rejection showed trends toward higher BK viremia (6.0 % vs 1.6 % ), whereas patients with chronic active antibody -mediated rejection had more new -onset diabetes after transplant (21.3 % vs 8.0 % ). At presentation, patients with chronic active antibody-mediated rejection had worse graft function (creatinine 176 vs 139 μmol /L; P = .013 ). Despite divergent initial management, both groups converged at 5 years with no significant difference in graft function or survival; overall graft loss exceeded 70% in both groups (P > .05 ).
CONCLUSIONS: Late and chronic active antibody -mediated rejection received different treatment intensities based on perceived acuity, yet both groups had similarly poor 5 -year outcomes with >70 % graft failure. These findings challenge current therapeutic paradigms and emphasize the urgent need for earlier diagnosis and more effective agents beyond standard regimens of steroids, plasma exchange, intravenous immunoglobulin, and rituximab.
MATERIALS AND METHODS: This single -center retrospective cohort study included 111 kidney transplant recipients with biopsy-proven antibody -mediated rejection (50 late, 61 chronic active ) between 2009 and 2024. Groups were matched on baseline demographics, donor type, comorbidities, and maintenance immunosuppression. Outcomes included treatment intensity, complications, renal function, and 5 -year graft survival.
RESULTS: Both groups had comparable baseline characteristics. Patients with late antibody-mediated rejection received significantly more intensive therapy: higher rituximab use (52.0 % vs 34.4 %; P = . ⁰⁰¹ ), more plasma exchange sessions (5.04 vs 2.11; P < . ⁰⁰¹ );, and higher rituximab doses (513.4 vs 252.6 mg; P = . ⁰⁰⁴ ). Patients with late antibody -mediated rejection showed trends toward higher BK viremia (6.0 % vs 1.6 % ), whereas patients with chronic active antibody -mediated rejection had more new -onset diabetes after transplant (21.3 % vs 8.0 % ). At presentation, patients with chronic active antibody-mediated rejection had worse graft function (creatinine 176 vs 139 μmol /L; P = .013 ). Despite divergent initial management, both groups converged at 5 years with no significant difference in graft function or survival; overall graft loss exceeded 70% in both groups (P > .05 ).
CONCLUSIONS: Late and chronic active antibody -mediated rejection received different treatment intensities based on perceived acuity, yet both groups had similarly poor 5 -year outcomes with >70 % graft failure. These findings challenge current therapeutic paradigms and emphasize the urgent need for earlier diagnosis and more effective agents beyond standard regimens of steroids, plasma exchange, intravenous immunoglobulin, and rituximab.